Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | PAK4 | O96013 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.32 |
| ▸ | FLT1 | P17948 | 2/20 | 0.32 |
| ▸ | LTK | P29376 | 2/20 | 0.32 |
| ▸ | GRK5 | P34947 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.32 |
| ▸ | CDK8 | P49336 | 2/20 | 0.32 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23532189 | 0.76 | HTT (0.33) | HTTKMT2ADYRK1AAURKADAPK3 | |
| SCHEMBL31033284 | 0.76 | DYRK1A (0.30) | DYRK1A | |
| SCHEMBL12062642 | 0.73 | CYP11B1 (0.38) | DYRK1AAURKADAPK3JAK2MAP4K4 | |
| SCHEMBL31033281 | 0.73 | CYP11B1 (0.38) | DYRK1AAURKADAPK3JAK2MAP4K4 | |
| SCHEMBL25352498 | 0.69 | NNMT (0.57) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL27867471 | 0.68 | — | — | |
| SCHEMBL30481014 | 0.67 | — | — | |
| SCHEMBL8320212 | 0.67 | DYRK1A (0.37) | HTTKMT2ADYRK1AAURKADAPK3 | |
| SCHEMBL23532183 | 0.67 | HTT (0.33) | HTTKMT2ADYRK1AAURKADAPK3 | |
| SCHEMBL31497990 | 0.66 | AKR1B1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160101092-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-04-14 | — | — | US | disclosed |
| US-20160101092-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101092-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | HTT 4223/4885KMT2A 2698/4885DYRK1A 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.